“설명가능 인공지능(XAI)”을 이용한 희귀질환 치료제 개발을 위한 Abzu와 콘테라파마의 RNA 치료제 개발 파트너십 체결

Abzu는 가장 진보한 AI기술인 “설명가능 인공지능(XAI)”을 개발하는 스타트업 회사이며, 콘테라파마는 신경질환 분야의 혁신적인 신약을 개발하는 회사로, 양사는 핵산(Nucleic Acid) 기반의 신약개발을 위한 파트너십을 체결했다.

Contera Pharma elected new executive management team

Contera Pharma, a subsidiary of Bukwang, announced that it elected Dr. Thomas Sager as CEO while further expanding the executive management team to include representatives for Business Development and R&D Chief Executive Officer; Thomas Sager, PhD. Chief Business Officer; Anders Brandt Elvang, PhD. Chief Science Officer; Kenneth Vielsted Christensen, PhD. Thomas Sager, received his PhD […]

Contera Pharma, subsidiary of Bukwang, raises 51 billion KRW in Series B financing round

Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional investors. The size of the current round has increased more than 17-fold compared to series A financing in 2019. Contera, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The […]

Contera Pharma opens office in Seoul, Korea

To strengthen its activities Contera Pharma has today opened an office in Seoul, Korea. The Seoul office will be headed by Minchang Kwon, Managing Director and Jai Hong Kwon, CFO. John Bondo Hansen, CEO says: Our new Seoul office will be a valuable addition to the Contera organization. I warmly welcome Minchang Kwon and Jai […]

Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND

Contera Pharma is preparing for public offering in KOSDAQ Bukwang has recently received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase 2 clinical study of JM-010. JM-010, originating from a Danish bioventure company Contera Pharma, is currently under development for treating dyskinesia which emerges in […]